BioNTech Pre-Announces Positive Late-Stage Oncology Data for Pumitamig and Gotistobart at ASCO

summarizeSummary

BioNTech pre-announced positive clinical data for its late-stage oncology candidates, Pumitamig and Gotistobart, which will be presented at the upcoming ASCO Annual Meeting. This includes clinically meaningful overall survival data for Gotistobart in ovarian cancer.

check_boxKey Events

• Pumitamig Shows Encouraging Activity

  Interim analysis from the Phase 2 dose-optimization part of the global Phase 2/3 ROSETTA Lung-02 trial showed encouraging anti-tumor activity for pumitamig plus chemotherapy in first-line non-small cell lung cancer (NSCLC).

• Gotistobart Demonstrates Overall Survival Benefit

  Phase 2 PRESERVE-004 trial data for gotistobart plus pembrolizumab in platinum-resistant ovarian cancer (PROC) showed durable anti-tumor activity and clinically meaningful overall survival outcomes.

• Late-Stage Pipeline Advancement

  BioNTech continues to advance its oncology pipeline with over 25 Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials and novel combination approaches.

• ASCO Presentation Details

  New clinical data and trial updates will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 29 to June 2, with two oral presentations highlighting pumitamig and gotistobart.

auto_awesomeAnalysis

BioNTech announced encouraging clinical data for two key late-stage oncology assets ahead of the ASCO Annual Meeting. The report of "clinically meaningful overall survival outcomes" for Gotistobart in platinum-resistant ovarian cancer and "encouraging anti-tumor activity" for Pumitamig in non-small cell lung cancer are significant positive developments for the company's pipeline. This news provides a much-needed positive signal for BioNTech, which has recently faced challenges including a Q1 net loss, a major workforce reduction, and leadership transitions.